

To,
BSE Limited
P.J. Towers,
Dalal Street, Mumbai — 400001

Date: 17.11.2024

Dear Sir/ Madam,

Sub: Un-Audited Financial Results for the Quarter ended 31.12.2023

Unit: Sangam Health Care Products Limited (Scrip Code: 531625)

With reference to the subject cited, please find attached the un audited financial results for the quarter ended 31.12.2023.

This is for the information and records of the Exchange, please.

Thanking you.

Yours truly,

For Sangam Health Care Products Limited


A. Bala Gopal
Chief Executive officer





LIMITED REVIEW REPORT

To,
The Board of Directors,
SANGAM HEALTH CARE PRODUCTS LIMITED

We have reviewed the accompanying statement of Un-Audited Financial Results of **SANGAM HEALTH CARE PRODUCTS LIMITED** or the quarter ended **31st December, 2023** attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing obligations and disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **M M REDDY & CO.,**
Chartered Accountants
Firm Reg No.: 010371S

M. Madhusudhana Reddy
Partner
Membership No. 213077
UDIN: 24213077BKBHGR6423



Place: Hyderabad
Date: 17-07-2024.




SANGAM HEALTH CARE PRODUCTS LIMITED					
205 & 206, AMARCHAND SHARMA COMPLEX, S.P. ROAD, SECUNDERABAD					
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2023					
(Rs.In Lakhs)					
	Particulars	Quarter Ended			Year Ended
		31-12-2023 Un-Audited	30.09.2023 Un-Audited	31-12-2022 Un-Audited	31-03-2023 Audited
1	Income from Operations				
(a)	Net Sales/Income from Operations	353.29	304.65	295.12	1,075.99
(b)	Other Income-	-	-	-	-
	Total Income	353.29	304.65	295.12	1,075.99
2	Expenditure				
(a)	Cost of Raw material consumed	170.99	165.39	149.47	494.61
(b)	Purchase of stock-in-trade	-	-	-	-
(c)	Change in inventories of Finished Goods Works-in Progress and Stock in Trade	-	-	-	-
(d)	Employees Benefit Expenses	40.49	37.58	83.84	303.10
(e)	Finance Cost	0.56	0.44	-	3.01
(f)	Depreciation and Amortization Expenses	30.43	30.43	30.43	121.72
(g)	Other Expenditure	55.10	50.57	57.35	290.04
	Total expenses	297.58	284.41	321.10	1,212.48
3	Profit from Operations before Extraordinary Items and Exceptional Items (1-2)	55.71	20.23	(25.98)	(136.49)
4	Exceptional Items	-	-	-	-
9	Profit / (Loss) from Ordinary Activities before tax (7+8)	55.71	20.23	(25.98)	(136.49)
10	Current tax	-	-	0.82	20.10
	Deferred tax	-	-	-	-
11	Net Profit (+)/Loss(-) from Ordinary Activities After Tax (9-10)	55.71	20.23	(26.80)	(116.39)
12	Paid up equity share capital (no of shares) (face value of the share Rs.10/-)	1486.07	1486.07	1486.07	1,486.07
13	Reserves excluding revaluation reserves	NIL	NIL	NIL	NIL
14	Earning Per Share (EPS)	0.37	0.14	-0.18	-0.78
	a) Basic and diluted Eps before Extraordinary (not to be annualized)				
	b) Basic and diluted Eps after Extraordinary (not to be annualized)				

Note :

- The above results were reviewed by the Audit Committee and taken on record by the Board of Directors at the meeting held on 17-07-2024
- The Limited Review of the Financials has been carried out by the Statutory Auditors of the Company in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Previous Accounting period's figures have been grouped/regrouped wherever considered necessary.

Place : Hyderabad
Date : 17-07-2024


 For Sangam HealthCare Products Limited
 Chairman and Managing Director